CA2243313A1 - Compositions and methods for the prevention and treatment of atherosclerosis and reperfusion injury with magnesium salts - Google Patents
Compositions and methods for the prevention and treatment of atherosclerosis and reperfusion injury with magnesium salts Download PDFInfo
- Publication number
- CA2243313A1 CA2243313A1 CA 2243313 CA2243313A CA2243313A1 CA 2243313 A1 CA2243313 A1 CA 2243313A1 CA 2243313 CA2243313 CA 2243313 CA 2243313 A CA2243313 A CA 2243313A CA 2243313 A1 CA2243313 A1 CA 2243313A1
- Authority
- CA
- Canada
- Prior art keywords
- magnesium gluconate
- administered
- atherosclerosis
- reperfusion injury
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 58
- 201000001320 Atherosclerosis Diseases 0.000 title claims abstract description 34
- 206010063837 Reperfusion injury Diseases 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title abstract description 23
- 230000002265 prevention Effects 0.000 title abstract description 14
- 159000000003 magnesium salts Chemical class 0.000 title description 4
- 239000001755 magnesium gluconate Substances 0.000 claims abstract description 43
- 229960003035 magnesium gluconate Drugs 0.000 claims abstract description 43
- 235000015778 magnesium gluconate Nutrition 0.000 claims abstract description 43
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 claims abstract description 43
- 239000001301 oxygen Substances 0.000 claims abstract description 21
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 21
- -1 oxygen free radical Chemical class 0.000 claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 claims abstract description 17
- 230000000302 ischemic effect Effects 0.000 claims abstract description 15
- 239000007864 aqueous solution Substances 0.000 claims abstract description 13
- 238000002399 angioplasty Methods 0.000 claims abstract description 12
- 208000037803 restenosis Diseases 0.000 claims abstract description 10
- 230000000747 cardiac effect Effects 0.000 claims abstract description 6
- 230000003511 endothelial effect Effects 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 15
- 210000004351 coronary vessel Anatomy 0.000 claims description 5
- 238000001356 surgical procedure Methods 0.000 abstract description 20
- 230000003859 lipid peroxidation Effects 0.000 abstract description 8
- 230000003902 lesion Effects 0.000 description 16
- 150000002632 lipids Chemical class 0.000 description 14
- 150000003254 radicals Chemical class 0.000 description 13
- 102000007330 LDL Lipoproteins Human genes 0.000 description 10
- 108010007622 LDL Lipoproteins Proteins 0.000 description 10
- 230000003143 atherosclerotic effect Effects 0.000 description 10
- 230000006378 damage Effects 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000010410 reperfusion Effects 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 208000028867 ischemia Diseases 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 229940118019 malondialdehyde Drugs 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 230000005779 cell damage Effects 0.000 description 4
- 210000003038 endothelium Anatomy 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 3
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 230000035508 accumulation Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229940091250 magnesium supplement Drugs 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 235000012209 glucono delta-lactone Nutrition 0.000 description 2
- 239000000182 glucono-delta-lactone Substances 0.000 description 2
- 229960003681 gluconolactone Drugs 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 150000002432 hydroperoxides Chemical class 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 208000037906 ischaemic injury Diseases 0.000 description 2
- 230000003520 lipogenic effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 235000011147 magnesium chloride Nutrition 0.000 description 2
- 229960005336 magnesium citrate Drugs 0.000 description 2
- 239000004337 magnesium citrate Substances 0.000 description 2
- 235000002538 magnesium citrate Nutrition 0.000 description 2
- 150000002681 magnesium compounds Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 238000005502 peroxidation Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000008458 response to injury Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000996834 Homo sapiens Linker for activation of T-cells family member 2 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010022680 Intestinal ischaemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 102100034238 Linker for activation of T-cells family member 2 Human genes 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000036778 atheroma formation Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940030602 cardiac therapy drug Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000008069 intimal proliferation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000012977 invasive surgical procedure Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention provides compositions and methods for the prevention or treatment of atherosclerosis and reperfusion injury. The method comprises administering to a patient having atherosclerosis an aqueous solution containing magnesium gluconate in an amount sufficient to inhibit oxygen free radical production and lipid peroxidation. In another embodiment the invention provides for the prevention of restenosis in patients undergoing bypass surgery or angioplasty. In a different embodiment, the present invention provides a method for prevention or treatment of ischemic reperfusion injury comprising the step of administering to a patient at risk of reperfusion injury a therapeutically effective amount of magnesium gluconate to inhibit oxygen free radical production. The aqueous solution of the invention comprises magnesium gluconate in an amount sufficient to inhibit oxygen free radical production in cardiac and endothelial tissues.
Description
WO 9?/2595g PCT/US97/00821 CO~PO~ITIONS AND hh.n~8 FOR THE PREVENTION
AND ~REA~ENT OF ~U~Do~rRp~I8 AND
REPERFU8ION INJURY WITH ~AGNE8TUM ~A~T8 ~. INTRODUCTION
The present invention relates to compositions and methods for the prevention and/or treatment of atherosclerosis. The method comprises administering to a patient having atherosclerosis an aqueous solution containing magnesium gluconate in an amount sufficient to inhibit lipid peroxidation and oxidative modification of lipoproteins. The present invention also provides methods for the prevention of restenosis in a patient undergoing a surgical procedure to treat atherosclerosis. In another embodiment, the present invention provides a method for prevention and/or treatment of ischemic reperfusion injury. The method comprises administering to a patient at risk of reperfusion injury an aqueous solution containing magnesium gluconate in an effective amount to limit anticipated ischemic injury and/or after the onset of an ischemic event.
AND ~REA~ENT OF ~U~Do~rRp~I8 AND
REPERFU8ION INJURY WITH ~AGNE8TUM ~A~T8 ~. INTRODUCTION
The present invention relates to compositions and methods for the prevention and/or treatment of atherosclerosis. The method comprises administering to a patient having atherosclerosis an aqueous solution containing magnesium gluconate in an amount sufficient to inhibit lipid peroxidation and oxidative modification of lipoproteins. The present invention also provides methods for the prevention of restenosis in a patient undergoing a surgical procedure to treat atherosclerosis. In another embodiment, the present invention provides a method for prevention and/or treatment of ischemic reperfusion injury. The method comprises administering to a patient at risk of reperfusion injury an aqueous solution containing magnesium gluconate in an effective amount to limit anticipated ischemic injury and/or after the onset of an ischemic event.
2 . R~ ~4POUND OF THE INVENTION
The present invention relates generally to the prevention and/or treatment of cardiovascular disease. More specifically, the present invention relates to compositions and methods of prevention and/or treatment of atherosclerosis and reperfusion injury.
Cardiovascular disease is the leading cause of death in the United States. Atherosclerotic heart disease is among the most serious and costly health problems in industrialized nations. Atherosclerosis is not a single disease entity. Atherosclerotic lesions take different forms, depending upon their anatomic site, the age, genetic and physiological status of the affected individual, and upon the risk factors to which each individual may have been exposed. The lesions of atherosclerosis occur principally within the intima and include the fatty streak, the fibrous plaque and the complicated plaques. Ross, R. and Blomset, J.A., 1976, N. Engl.
J. Med. 295: 369.
Lipids play a central role in the pathogenesis of atherosclerosis, especially in individuals with markedly increased elevations of plasma low-density lipoproteins (LDL). The accumulation of lipid within proliferated smooth muscle cells, within macrophages in the lesions, and within the extracellular connective tissue matrix, are common findings in atherosclerotic lesions.
Geer, J.C. et al., 1961, Am. ~. Pathol. 38: 263.
Injury to the endothelium that results in alterations in permeability permits plasma constituents such as lipoproteins to have more ready access to the artery wall. Oxidation of LDL is one of the deleterious effects of oxidative stress. Free radicals released from injured endothelial cells, smooth muscle cells and macrophages induce peroxidation of LDL lipids, resulting in formation of hydroperoxides of arachidonic acid and other unsaturated lipid moieties of LDL lipids. Steinbrecher, U.P. et al., 1984, Proc. Natl. Acad. Sci. USA 81: 3883; Morel, D.W. et al., 1984, Arteriosclerosis 4: 375.
A number of pharmaceutical interventions have been proposed for prevention and/or treatment of atherosclerosis. In many cases of atherosclerosis, invasive surgical procedures of bypass or angioplasty are required to reestablish an occluded lumen to proper size. At present, more than 220,000 patients W097/25959 PCT~S97/~821 per year undergo coronary artery bypass surgery in the United States. Virtually all grafts early after implantation show loss of endothelium and deposition of fibrin and platelet thrombi to form a plaque. In some patients the circumferential intimal plaque continues to proliferate in the ensuing months and in some cases this leads to significant narrowing of the graft lumen or restenosis, by an atherosclerotic process. Forty percent of patients have restenosed arteries within 5 years of bypass grafts. Bulkley, .H. et al., 1977 , Circulation 55: 163.
Coronary angioplasty is an effective method of improving blood flow to the heart. However, changes in the structure of the vessel wall after angioplasty include intimal proliferation, deposition of thrombi and thrombosis. In approximately 30 percent of patients restenosis occurs within three to six months.
Cardiac tissue is susceptible to ischemia wherein the tissue suffers from a decrease or cessation of perfusion by blood due to blockage of the blood vessels by atherosclerosis, heart attack, stroke, during tissue neurosis, or organ transplant.
A cardiac ischemic event can also be caused from therapeutic interventions such as bypass surgery or angioplasty.
Clinical and experimental studies have indicated that timely reperfusion of ischemic myocardium can reduce the amount of necrosis after acute coronary artery occlusion. Kloner, R.A., et al., 1983 Circulation 68 (Suppl I) I-8. However, reperfusion, while terminating ischemia, can also cause further damage to jeopardized cells. Frame, L.H. et al., 1983, J. Clin . Invest . 72 : 535. This phenomenon has been termed "reperfusion injury'l.
Several m~ch~nisms have been proposed to explain its W097/25959 PCT~S97/00821 occurrence after bypass surgery and angioplasty, including cell swelling due to sodium and water influx, calcium influx and formation of calcium phosphate granules within mitochondria, hemorrhage, and generation of oxygen free radicals, particularly superoxide anions ( ~~2-) at the time of reoxygenation.
There is increasing evidence that hypoxia or ischemia followed by reoxygenation or reperfusion increases production of oxygen radical species. The production of oxygen radicals and lipid peroxides during reperfusion are believed to result in tissue necrosis or damage. Administration of exogenous quenchers of free radicals, such as superoxide dismutase, catalase or both, improve cardiac function and limit infarct size when administered after global ischemia. McCord, J.M., 1985, 312: 159-163; Jolly, S.R., et al., 1984, Cir. ~es. 54: 277-285. Other examples of clinically significant ischemic reperfusion injury include intestinal ischemia, necrotic brain-tissue, damage to the organ during organ transplantation or ischemic injuries in patients receiving artificial blood substitutes.
The present invention relates generally to the prevention and/or treatment of cardiovascular disease. More specifically, the present invention relates to compositions and methods of prevention and/or treatment of atherosclerosis and reperfusion injury.
Cardiovascular disease is the leading cause of death in the United States. Atherosclerotic heart disease is among the most serious and costly health problems in industrialized nations. Atherosclerosis is not a single disease entity. Atherosclerotic lesions take different forms, depending upon their anatomic site, the age, genetic and physiological status of the affected individual, and upon the risk factors to which each individual may have been exposed. The lesions of atherosclerosis occur principally within the intima and include the fatty streak, the fibrous plaque and the complicated plaques. Ross, R. and Blomset, J.A., 1976, N. Engl.
J. Med. 295: 369.
Lipids play a central role in the pathogenesis of atherosclerosis, especially in individuals with markedly increased elevations of plasma low-density lipoproteins (LDL). The accumulation of lipid within proliferated smooth muscle cells, within macrophages in the lesions, and within the extracellular connective tissue matrix, are common findings in atherosclerotic lesions.
Geer, J.C. et al., 1961, Am. ~. Pathol. 38: 263.
Injury to the endothelium that results in alterations in permeability permits plasma constituents such as lipoproteins to have more ready access to the artery wall. Oxidation of LDL is one of the deleterious effects of oxidative stress. Free radicals released from injured endothelial cells, smooth muscle cells and macrophages induce peroxidation of LDL lipids, resulting in formation of hydroperoxides of arachidonic acid and other unsaturated lipid moieties of LDL lipids. Steinbrecher, U.P. et al., 1984, Proc. Natl. Acad. Sci. USA 81: 3883; Morel, D.W. et al., 1984, Arteriosclerosis 4: 375.
A number of pharmaceutical interventions have been proposed for prevention and/or treatment of atherosclerosis. In many cases of atherosclerosis, invasive surgical procedures of bypass or angioplasty are required to reestablish an occluded lumen to proper size. At present, more than 220,000 patients W097/25959 PCT~S97/~821 per year undergo coronary artery bypass surgery in the United States. Virtually all grafts early after implantation show loss of endothelium and deposition of fibrin and platelet thrombi to form a plaque. In some patients the circumferential intimal plaque continues to proliferate in the ensuing months and in some cases this leads to significant narrowing of the graft lumen or restenosis, by an atherosclerotic process. Forty percent of patients have restenosed arteries within 5 years of bypass grafts. Bulkley, .H. et al., 1977 , Circulation 55: 163.
Coronary angioplasty is an effective method of improving blood flow to the heart. However, changes in the structure of the vessel wall after angioplasty include intimal proliferation, deposition of thrombi and thrombosis. In approximately 30 percent of patients restenosis occurs within three to six months.
Cardiac tissue is susceptible to ischemia wherein the tissue suffers from a decrease or cessation of perfusion by blood due to blockage of the blood vessels by atherosclerosis, heart attack, stroke, during tissue neurosis, or organ transplant.
A cardiac ischemic event can also be caused from therapeutic interventions such as bypass surgery or angioplasty.
Clinical and experimental studies have indicated that timely reperfusion of ischemic myocardium can reduce the amount of necrosis after acute coronary artery occlusion. Kloner, R.A., et al., 1983 Circulation 68 (Suppl I) I-8. However, reperfusion, while terminating ischemia, can also cause further damage to jeopardized cells. Frame, L.H. et al., 1983, J. Clin . Invest . 72 : 535. This phenomenon has been termed "reperfusion injury'l.
Several m~ch~nisms have been proposed to explain its W097/25959 PCT~S97/00821 occurrence after bypass surgery and angioplasty, including cell swelling due to sodium and water influx, calcium influx and formation of calcium phosphate granules within mitochondria, hemorrhage, and generation of oxygen free radicals, particularly superoxide anions ( ~~2-) at the time of reoxygenation.
There is increasing evidence that hypoxia or ischemia followed by reoxygenation or reperfusion increases production of oxygen radical species. The production of oxygen radicals and lipid peroxides during reperfusion are believed to result in tissue necrosis or damage. Administration of exogenous quenchers of free radicals, such as superoxide dismutase, catalase or both, improve cardiac function and limit infarct size when administered after global ischemia. McCord, J.M., 1985, 312: 159-163; Jolly, S.R., et al., 1984, Cir. ~es. 54: 277-285. Other examples of clinically significant ischemic reperfusion injury include intestinal ischemia, necrotic brain-tissue, damage to the organ during organ transplantation or ischemic injuries in patients receiving artificial blood substitutes.
3. 8UMMARY OF THE INVENTION
The present invention relates to compositions and methods for the prevention and/or treatment of atherosclerosis and/or reperfusion injury.
More specifically, the present invention provides a method of preventing the initiation and/or progression of atherosclerotic lesions. The present invention also provides a method for preventing the restenosis of coronary vessels following angioplasty or bypass surgery. To this end, the present invention provides a method comprising administering to a patient having atherosclerosis an aqueous W097/259s9 PCT~S97100821 solution containing magnesium gluconate in sufficient amounts to inhibit oxygen free radical production and lipid peroxidation. In different embodiments of the invention, the composition is administered enterally or parenterally.
In another embodiment of the invention, a method is provided for preventing restenosis in a patient undergoing a surgical procedure for treatment of atherosclerosis, comprising administering to the patient before and after the surgical procedure a therapeutically effective amount of magnesium gluconate.
The present invention also provides a method for treating and/or reducing ischemic reperfusion injury comprising administering to a patient undergoing a surgical procedure and in danger of reperfusion injury, a therapeutically effective amount of magnesium gluconate to inhibit oxygen free radical production. In different embodiments of the method the surgical procedures are bypass surgery and angioplasty.
The compositions of the invention comprise aqueous solutions suitable for enteral or parenteral administration containing magnesium gluconate in an amount sufficient to inhibit oxygen free radical production and lipid peroxidation in cardiac and endothelial tissues.
The examples presented in Sections 5 and 6 below detail the use according to the methods of the invention of magnesium gluconate in clinical and experimental models of atherosclerosis and reperfusion injury.
The present invention relates to compositions and methods for the prevention and/or treatment of atherosclerosis and/or reperfusion injury.
More specifically, the present invention provides a method of preventing the initiation and/or progression of atherosclerotic lesions. The present invention also provides a method for preventing the restenosis of coronary vessels following angioplasty or bypass surgery. To this end, the present invention provides a method comprising administering to a patient having atherosclerosis an aqueous W097/259s9 PCT~S97100821 solution containing magnesium gluconate in sufficient amounts to inhibit oxygen free radical production and lipid peroxidation. In different embodiments of the invention, the composition is administered enterally or parenterally.
In another embodiment of the invention, a method is provided for preventing restenosis in a patient undergoing a surgical procedure for treatment of atherosclerosis, comprising administering to the patient before and after the surgical procedure a therapeutically effective amount of magnesium gluconate.
The present invention also provides a method for treating and/or reducing ischemic reperfusion injury comprising administering to a patient undergoing a surgical procedure and in danger of reperfusion injury, a therapeutically effective amount of magnesium gluconate to inhibit oxygen free radical production. In different embodiments of the method the surgical procedures are bypass surgery and angioplasty.
The compositions of the invention comprise aqueous solutions suitable for enteral or parenteral administration containing magnesium gluconate in an amount sufficient to inhibit oxygen free radical production and lipid peroxidation in cardiac and endothelial tissues.
The examples presented in Sections 5 and 6 below detail the use according to the methods of the invention of magnesium gluconate in clinical and experimental models of atherosclerosis and reperfusion injury.
4. DEBCRIPTION OF THE FIGURES
Figure 1. Effects of magnesium salts formation of malondialdehyde in endothelial cell membranes.
Figure 2. Effects of magnesium salts on site-specific OH.-mediated deoxyribose oxidation.
Figure 1. Effects of magnesium salts formation of malondialdehyde in endothelial cell membranes.
Figure 2. Effects of magnesium salts on site-specific OH.-mediated deoxyribose oxidation.
5. DET~r~n Dh~CRTPTION OF THE Ih~ ON
The present invention relates to compositions and methods for the prevention and/or treatment of atherosclerosis and reperfusion injury.
More specifically, the present invention provides a method of preventing the initiation and/or progression of atherosclerotic lesions.
The lesions of atherosclerosis occur principally within intima and include the fatty streak, the fibrous plaque and the complicated plaques. Fatty streaks are accumulations of lipid laden myointimal cells at branch points of vessels and can be identified at any age or sex. The fatty streak is ubiquitous in young people and does not inevitably lead to advanced lesions of atherosclerosis, but is of interest as a possible precursor of advanced atherosclerotic lesions.
Fibrous plaques develop around the age of 25 in those populations in which there is a high incidence of atherosclerosis. The fibrous plaques WO 9712S959 rCT/US97/00821 are white and viewed as a more advanced atherosclerotic lesion with potential for lumina narrowing and degeneration. The fibrous plaques are derived from fatty streaks that continue the process of cell proliferation, lipid accumulation and connective tissue formation. The third and most advanced atheroma is the complicated plaque, composed of fibrous tissue, fibrin, calcium, intracellular and extracellular lipid, and having a necrotic lipid-rich core. The lesions may disintegrate and ulcerate and become involved with thrombotic episodes that may lead to occlusive disease.
There are three pathogenic theories of atheroma formation: the lipogenic theory, the response-to-injury theory, and the monoclonal theory.
The monoclonal theory suggests that each atherosclerotic lesion is derived from a single smooth-muscle cell and this cell serves as the progenitor for all of the proliferating cells within the lesion.
The lipogenic theory implicates lipids in the initiation and progression of atherosclerosis in individuals with markedly increased elevations of plasma low-density lipoproteins (LDL). The accumulation of lipid within proliferated smooth muscle cells, within macrophages in the lesions, and within the extracellular connective tissue matrix, CA 022433l3 l998-07-l7 W097l25959 PCT~S97100821 are common findings in lesions of atherosclerosis.
Geer, J.C., et al., 1961, Am. J. Pathol. 38:263.
The response-to-injury theory suggests some form of "injury" to the endothelium which results in structural and/or functional alterations in the endothelial cells. Ross, H. and Harker, L., 1976, Science 193: 1094. Injury to the endothelium that results in alterations in permeability permits plasma constituents such as lipoproteins to have more ready access to the artery wall. Oxidation of LDL is one of the deleterious effects of oxidative stress.
Oxygen free radicals released from injured endothelial cells, smooth muscle cells and macrophages induce peroxidation of LDL lipids, resulting in formation of hydroperoxides of arachidonic acid and other unsaturated lipid moieties of LDL lipids.
The present invention provides a method of preventing the initiation and/or progression of atherosclerosis by inhibiting oxygen free radical production by cardiac tissue, endothelial cells and cellular elements in the atherosclerotic lesions such as macrophages and neutrophil leukocytes.
A free radical is a molecule with an odd, unpaired electron which makes the molecule unstable and highly reactive. Tribble, D.L., et al., 1987, ~epatology 7: 377-386. Small amounts of these W097125959 PCT~S97/00821 compounds are produced endogenously by the mitochondrial electron transport system and the endoplasmic reticulum in microsomes and peroxisomes.
Oxygen free radicals, the superoxide anion (~2-), the hydroxyl radical (~OH), and their intermediary, hydrogen peroxide (H2O2), are believed to be generated during ischemia and at the time of reperfusion.
These free radicals interact with other cellular constituents such as deoxyribonucleic acid (DNA) and lipids with subse~uent formation of multiple degradation products. Lipid peroxidation forms lipid peroxides and aldehydes that interact with protein sulfhydryl groups perpetuating cellular damage. Del Maestro, R.F., 1980, Acta. Physiol. Scan~. 492 (Suppl.): 153-168.
Normally, protective mechanisms are present in the cell to prevent damage by free radicals. For example, the primary mechanism of clearance of ~2-from biologic systems is superoxide dismutase, which catalyzes the dismutation ~f ~2- to H2O2 and ~2- The cytoplasmic enzymes glutathione peroxidase and catalase provide the final detoxification steps with the reduction of H2O2 to ~2- Glutathione peroxidase seems to be a more active enzyme than catalase in protecting myocardial cells from H2O2-mediated damage.
Fridovich, I., 1983, Annu. ~ev. Pharmacol. ~oxicol.
WO 97!25959 PCT/US97/00821 23: 239-257; Fantone, J.C., et al., 1982, Am. J.
Pathol . 107: 395-418.
The present invention provides a method comprising administering to a patient having atherosclerosis a composition of the invention containing magnesium gluconate in sufficient amounts to inhibit oxygen free radical production and lipid peroxidation associated with it.
The present invention also provides a method for preventing and treating restenosis of coronary vessel following angioplasty or bypass surgery. To that end, the present invention provides methods for preventing or treating restenosis in a patient undergoing a surgical procedure for treatment of atherosclerosis, comprising administering to the patient prior to and/or after the surgical procedure, a therapeutically effective amount of magnesium gluconate.
In different embodiments of the invention, the composition of the invention is administered enterally or parenterally in the prevention or treatment of atherosclerosis.
The compositions of the invention comprise aqueous solutions containing magnesium gluconate in an amount sufficient to inhibit oxygen free radical production and lipid peroxidation in cardiac and endothelial tissues.
Wo97!25959 PCT~$97/00821 The present invention also provides compositions and methods for preventing or treating ischemic reperfusion injury. By definition, reperfusion injury refers to cell death or damage caused by reperfusion, in contrast to cell death or damage caused by the preceding ischemic episode. The mPch~ni~m by which reperfusion injury occurs involves the generation of oxygen free radicals when oxygen and blood elements are reintroduced into the ischemic bed at reperfusion. For example, during perfusion of the isolated heart, malondialdehyde, which is a byproduct of the lipid peroxidation, remains unchanged during hypoxia, but increases significantly during reoxygenation. Kloner, R.A., et al., 1983, Circulation 68: (Suppl. I): I-8 - I-15.
In a different embodiment, the present invention also provides a method for preventing and treating ischemic reperfusion injury comprising administering to a patient undergoing a surgical procedure and at risk of reperfusion injury a therapeutically effective amount of magnesium gluconate to inhibit oxygen free radical production.
In yet further embodiments, application of the methods of the invention include such procedures as bypass surgery and angioplasty.
Administration of magnesium gluconate results in cellular resistance to oxygen free radical WO 971259~;9 PCT/US97/00821 production and free radical stress. The preferred composition of the invention contains magnesium gluconate, desirably at a concentration of about 0.2mM to about 0.4M.
The present invention can ~e used as an adjunct with other cardiac therapy, e.g. with a thrombolytic drug administered to a patient who has had a myocardial infarction.
Magnesium is an important metallocoenzyme for may enzyme reactions. In the method of the present invention, magnesium gluconate inhibits the production of oxygen free radicals thereby reducing the cellular damage due to oxidative stress.
Our aqueous magnesium gluconate composition for enteral administration is obtained by mixing a suitable magnesium salt, for example, magnesium carbonate, with citric acid and glucono-delta-lactone. Desirably the following concentration ranges are utilized: magnesium carbonate in the range of 2mg per liter to 44g per liter; citric acid in the range of 2.3mg per liter to 46.2g per liter; and glucono-delta-lactone in the range of 6mg per liter to 25mg per liter. There results an aqueous solution of magnesium gluconate/citrate, i.e. a solution containing magnesium gluconate and magnesium citrate.
WO97!25959 PCT~S97/00821 Our other aqueous composition for parenteral administration comprises an aqueous solution of magnesium gluconate.
5.l PHARMACEUTICA~ PREPARATION~ AND
METHODB OF AD~INI8TRATION
The identified compositions that prevent or treat atherosclerosis or reperfusion injury can be administered to a patient at therapeutically effective doses. A therapeutically effective dose refers to that amount of the magnesium compound sufficient to result in the amelioration of symptoms of atherosclerosis or reperfusion injury.
Toxicity and therapeutic efficacy of the magnesium compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the EDso (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LDso/EDso. Compounds which exhibit large therapeutic indices are preferred. The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosages for use in humans.
5 . 2 FOR~IULATIONB
Pharmaceutical compositions for use in accordance with the present invention can be formulated in conventional manner using one or more physiologically acceptable carriers, excipients or buffers.
Thus, the compounds and their physiologically acceptable salts and solvates can be formulated for administration by insufflation (either through the mouth or the nose) or oral, buccal, parenteral or rectal administration.
For oral administration, the pharmaceutical compositions can take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate or talc); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate). The tablets can be coated by methods well known in the art. Liquid preparations for oral administration can take the form of, for example, aqueous solutions, syrups or suspensions, or they can be presented as a dry product for W097/2S959 PCT~S97/00821 constitution with water or other suitable vehicle before use. Such liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydrobenzoates or sorbic acid). The preparations can also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.
Preparations for oral administration can be formulated to give controlled release of the active compound.
~ or buccal administration the compositions can take the form of tablets or lozenges formulated in the conventional manner.
The compounds can be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection can be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions can take such forms as suspensions, solutions or emulsions in oily or a~ueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or W097125959 PCT~S97/00821 dispersing agents. Alternatively, the active ingredient can be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
The compounds can also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
In addition to the formulations described previously, the compounds can also be formulated as a depot preparation. Such long acting formulations can be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds can be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
The compositions can, if desired, be presented in a pack or dispenser device which can contain one or more unit dosage forms containing the active ingredient. The pack can for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device can be accompanied by instructions for administration.
WO 97/2~;959 PCT/US97/00821 6. EXANP~E: ~nNTNT8TRATION OF M~GP~IUM
GLUCONATE IN T~E TP~TMRNT OF
~u~Po~T.~P~
Patients with hypercholes~erolemia, complaining of shortness of breath and chest pain, are administered 88meqJ10Oml of magnesium gluconate 48 hours prior to the surgical procedure, and a divided dose up until time of surgery, i.e., bypass surgery or angioplasty. The total amount of magnesium gluconate given in the bolus injection depends on facts such as body weight, age, etc.
Plasma lipid peroxide level is measured as malondialdehyde prior to and after intervention with magnesium. During the surgical procedure, the occluded artery is perfused with the 4.4% magnesium gluconate solution. Intravenous magnesium gluconate solution is administered at the dose of 4.4%
depending on the clinical profile of the patient.
Follow-up arteriography is carried out to monitor the recovery. Depending on the results obtained, the therapeutic regimen is developed with the ultimate goal of preventing and treating reperfusion injury and atherosclerosis.
The present invention relates to compositions and methods for the prevention and/or treatment of atherosclerosis and reperfusion injury.
More specifically, the present invention provides a method of preventing the initiation and/or progression of atherosclerotic lesions.
The lesions of atherosclerosis occur principally within intima and include the fatty streak, the fibrous plaque and the complicated plaques. Fatty streaks are accumulations of lipid laden myointimal cells at branch points of vessels and can be identified at any age or sex. The fatty streak is ubiquitous in young people and does not inevitably lead to advanced lesions of atherosclerosis, but is of interest as a possible precursor of advanced atherosclerotic lesions.
Fibrous plaques develop around the age of 25 in those populations in which there is a high incidence of atherosclerosis. The fibrous plaques WO 9712S959 rCT/US97/00821 are white and viewed as a more advanced atherosclerotic lesion with potential for lumina narrowing and degeneration. The fibrous plaques are derived from fatty streaks that continue the process of cell proliferation, lipid accumulation and connective tissue formation. The third and most advanced atheroma is the complicated plaque, composed of fibrous tissue, fibrin, calcium, intracellular and extracellular lipid, and having a necrotic lipid-rich core. The lesions may disintegrate and ulcerate and become involved with thrombotic episodes that may lead to occlusive disease.
There are three pathogenic theories of atheroma formation: the lipogenic theory, the response-to-injury theory, and the monoclonal theory.
The monoclonal theory suggests that each atherosclerotic lesion is derived from a single smooth-muscle cell and this cell serves as the progenitor for all of the proliferating cells within the lesion.
The lipogenic theory implicates lipids in the initiation and progression of atherosclerosis in individuals with markedly increased elevations of plasma low-density lipoproteins (LDL). The accumulation of lipid within proliferated smooth muscle cells, within macrophages in the lesions, and within the extracellular connective tissue matrix, CA 022433l3 l998-07-l7 W097l25959 PCT~S97100821 are common findings in lesions of atherosclerosis.
Geer, J.C., et al., 1961, Am. J. Pathol. 38:263.
The response-to-injury theory suggests some form of "injury" to the endothelium which results in structural and/or functional alterations in the endothelial cells. Ross, H. and Harker, L., 1976, Science 193: 1094. Injury to the endothelium that results in alterations in permeability permits plasma constituents such as lipoproteins to have more ready access to the artery wall. Oxidation of LDL is one of the deleterious effects of oxidative stress.
Oxygen free radicals released from injured endothelial cells, smooth muscle cells and macrophages induce peroxidation of LDL lipids, resulting in formation of hydroperoxides of arachidonic acid and other unsaturated lipid moieties of LDL lipids.
The present invention provides a method of preventing the initiation and/or progression of atherosclerosis by inhibiting oxygen free radical production by cardiac tissue, endothelial cells and cellular elements in the atherosclerotic lesions such as macrophages and neutrophil leukocytes.
A free radical is a molecule with an odd, unpaired electron which makes the molecule unstable and highly reactive. Tribble, D.L., et al., 1987, ~epatology 7: 377-386. Small amounts of these W097125959 PCT~S97/00821 compounds are produced endogenously by the mitochondrial electron transport system and the endoplasmic reticulum in microsomes and peroxisomes.
Oxygen free radicals, the superoxide anion (~2-), the hydroxyl radical (~OH), and their intermediary, hydrogen peroxide (H2O2), are believed to be generated during ischemia and at the time of reperfusion.
These free radicals interact with other cellular constituents such as deoxyribonucleic acid (DNA) and lipids with subse~uent formation of multiple degradation products. Lipid peroxidation forms lipid peroxides and aldehydes that interact with protein sulfhydryl groups perpetuating cellular damage. Del Maestro, R.F., 1980, Acta. Physiol. Scan~. 492 (Suppl.): 153-168.
Normally, protective mechanisms are present in the cell to prevent damage by free radicals. For example, the primary mechanism of clearance of ~2-from biologic systems is superoxide dismutase, which catalyzes the dismutation ~f ~2- to H2O2 and ~2- The cytoplasmic enzymes glutathione peroxidase and catalase provide the final detoxification steps with the reduction of H2O2 to ~2- Glutathione peroxidase seems to be a more active enzyme than catalase in protecting myocardial cells from H2O2-mediated damage.
Fridovich, I., 1983, Annu. ~ev. Pharmacol. ~oxicol.
WO 97!25959 PCT/US97/00821 23: 239-257; Fantone, J.C., et al., 1982, Am. J.
Pathol . 107: 395-418.
The present invention provides a method comprising administering to a patient having atherosclerosis a composition of the invention containing magnesium gluconate in sufficient amounts to inhibit oxygen free radical production and lipid peroxidation associated with it.
The present invention also provides a method for preventing and treating restenosis of coronary vessel following angioplasty or bypass surgery. To that end, the present invention provides methods for preventing or treating restenosis in a patient undergoing a surgical procedure for treatment of atherosclerosis, comprising administering to the patient prior to and/or after the surgical procedure, a therapeutically effective amount of magnesium gluconate.
In different embodiments of the invention, the composition of the invention is administered enterally or parenterally in the prevention or treatment of atherosclerosis.
The compositions of the invention comprise aqueous solutions containing magnesium gluconate in an amount sufficient to inhibit oxygen free radical production and lipid peroxidation in cardiac and endothelial tissues.
Wo97!25959 PCT~$97/00821 The present invention also provides compositions and methods for preventing or treating ischemic reperfusion injury. By definition, reperfusion injury refers to cell death or damage caused by reperfusion, in contrast to cell death or damage caused by the preceding ischemic episode. The mPch~ni~m by which reperfusion injury occurs involves the generation of oxygen free radicals when oxygen and blood elements are reintroduced into the ischemic bed at reperfusion. For example, during perfusion of the isolated heart, malondialdehyde, which is a byproduct of the lipid peroxidation, remains unchanged during hypoxia, but increases significantly during reoxygenation. Kloner, R.A., et al., 1983, Circulation 68: (Suppl. I): I-8 - I-15.
In a different embodiment, the present invention also provides a method for preventing and treating ischemic reperfusion injury comprising administering to a patient undergoing a surgical procedure and at risk of reperfusion injury a therapeutically effective amount of magnesium gluconate to inhibit oxygen free radical production.
In yet further embodiments, application of the methods of the invention include such procedures as bypass surgery and angioplasty.
Administration of magnesium gluconate results in cellular resistance to oxygen free radical WO 971259~;9 PCT/US97/00821 production and free radical stress. The preferred composition of the invention contains magnesium gluconate, desirably at a concentration of about 0.2mM to about 0.4M.
The present invention can ~e used as an adjunct with other cardiac therapy, e.g. with a thrombolytic drug administered to a patient who has had a myocardial infarction.
Magnesium is an important metallocoenzyme for may enzyme reactions. In the method of the present invention, magnesium gluconate inhibits the production of oxygen free radicals thereby reducing the cellular damage due to oxidative stress.
Our aqueous magnesium gluconate composition for enteral administration is obtained by mixing a suitable magnesium salt, for example, magnesium carbonate, with citric acid and glucono-delta-lactone. Desirably the following concentration ranges are utilized: magnesium carbonate in the range of 2mg per liter to 44g per liter; citric acid in the range of 2.3mg per liter to 46.2g per liter; and glucono-delta-lactone in the range of 6mg per liter to 25mg per liter. There results an aqueous solution of magnesium gluconate/citrate, i.e. a solution containing magnesium gluconate and magnesium citrate.
WO97!25959 PCT~S97/00821 Our other aqueous composition for parenteral administration comprises an aqueous solution of magnesium gluconate.
5.l PHARMACEUTICA~ PREPARATION~ AND
METHODB OF AD~INI8TRATION
The identified compositions that prevent or treat atherosclerosis or reperfusion injury can be administered to a patient at therapeutically effective doses. A therapeutically effective dose refers to that amount of the magnesium compound sufficient to result in the amelioration of symptoms of atherosclerosis or reperfusion injury.
Toxicity and therapeutic efficacy of the magnesium compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the EDso (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LDso/EDso. Compounds which exhibit large therapeutic indices are preferred. The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosages for use in humans.
5 . 2 FOR~IULATIONB
Pharmaceutical compositions for use in accordance with the present invention can be formulated in conventional manner using one or more physiologically acceptable carriers, excipients or buffers.
Thus, the compounds and their physiologically acceptable salts and solvates can be formulated for administration by insufflation (either through the mouth or the nose) or oral, buccal, parenteral or rectal administration.
For oral administration, the pharmaceutical compositions can take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate or talc); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate). The tablets can be coated by methods well known in the art. Liquid preparations for oral administration can take the form of, for example, aqueous solutions, syrups or suspensions, or they can be presented as a dry product for W097/2S959 PCT~S97/00821 constitution with water or other suitable vehicle before use. Such liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydrobenzoates or sorbic acid). The preparations can also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.
Preparations for oral administration can be formulated to give controlled release of the active compound.
~ or buccal administration the compositions can take the form of tablets or lozenges formulated in the conventional manner.
The compounds can be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection can be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions can take such forms as suspensions, solutions or emulsions in oily or a~ueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or W097125959 PCT~S97/00821 dispersing agents. Alternatively, the active ingredient can be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
The compounds can also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
In addition to the formulations described previously, the compounds can also be formulated as a depot preparation. Such long acting formulations can be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds can be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
The compositions can, if desired, be presented in a pack or dispenser device which can contain one or more unit dosage forms containing the active ingredient. The pack can for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device can be accompanied by instructions for administration.
WO 97/2~;959 PCT/US97/00821 6. EXANP~E: ~nNTNT8TRATION OF M~GP~IUM
GLUCONATE IN T~E TP~TMRNT OF
~u~Po~T.~P~
Patients with hypercholes~erolemia, complaining of shortness of breath and chest pain, are administered 88meqJ10Oml of magnesium gluconate 48 hours prior to the surgical procedure, and a divided dose up until time of surgery, i.e., bypass surgery or angioplasty. The total amount of magnesium gluconate given in the bolus injection depends on facts such as body weight, age, etc.
Plasma lipid peroxide level is measured as malondialdehyde prior to and after intervention with magnesium. During the surgical procedure, the occluded artery is perfused with the 4.4% magnesium gluconate solution. Intravenous magnesium gluconate solution is administered at the dose of 4.4%
depending on the clinical profile of the patient.
Follow-up arteriography is carried out to monitor the recovery. Depending on the results obtained, the therapeutic regimen is developed with the ultimate goal of preventing and treating reperfusion injury and atherosclerosis.
7. EXANPLE: ADMINI8TRATION OF NAGNE8IUN
GLUCONATE IN EXP~T~NTAL MODEL8 OF
Cultured Endotheli~l Cell Membrane~
Endothelial cells were cultured in vitro in the presence of 0.25, 0.5, 1.0 and 2.0mM of magnesium W097l25959 PCT~S97/00821 salts including magnesium gluconate, magnesium chloride and magnesium sulfate. Membrane malondialdehyde and site specific OH.- mediated deoxyribose oxidate were measured according to methods described by Mak, I.T. & Weglicki, N.B., 1994, Method Enzymol. 234: 620-630; and Mak, I.T., et al., 1990, Biochem Pharm. 40: 2169-2175. Results demonstrate that magnesium gluconate is more effective than magnesium chloride or magnesium sulfate in inhibiting free radical production (malondialdehyde) (Figure 1) and in inhibiting free radical mediated deoxyribose oxidation in a dose dependent manner. (Figure 2).
The publications cited herein are incorporated by reference in their entireties.
The present invention is not to be construed as limited in scope to the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.
GLUCONATE IN EXP~T~NTAL MODEL8 OF
Cultured Endotheli~l Cell Membrane~
Endothelial cells were cultured in vitro in the presence of 0.25, 0.5, 1.0 and 2.0mM of magnesium W097l25959 PCT~S97/00821 salts including magnesium gluconate, magnesium chloride and magnesium sulfate. Membrane malondialdehyde and site specific OH.- mediated deoxyribose oxidate were measured according to methods described by Mak, I.T. & Weglicki, N.B., 1994, Method Enzymol. 234: 620-630; and Mak, I.T., et al., 1990, Biochem Pharm. 40: 2169-2175. Results demonstrate that magnesium gluconate is more effective than magnesium chloride or magnesium sulfate in inhibiting free radical production (malondialdehyde) (Figure 1) and in inhibiting free radical mediated deoxyribose oxidation in a dose dependent manner. (Figure 2).
The publications cited herein are incorporated by reference in their entireties.
The present invention is not to be construed as limited in scope to the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.
Claims (22)
1. A method for treating atherosclerosis comprising administering to a patient having atherosclerosis a therapeutically effective amount of magnesium gluconate to inhibit oxygen free radical production in cardiac and endothelial tissue.
2. The method of claim 1, wherein the magnesium gluconate is administered in an aqueous solution.
3. The method of claim 2, wherein the solution administered contains magnesium gluconate at a dose range of approximately 0.2mM to 0.4M.
4. The method of claim 2, wherein the solution is administered parenterally.
5. The method of claim 2, wherein the solution is administered enterally.
6. A method for treating atherosclerosis or restenosis comprising the step of administering to a patient prior to or after a coronary artery bypass or angioplasty therapeutically effective amount of magnesium gluconate.
7. The method of claim 6, wherein the magnesium gluconate is administered in an aqueous solution.
8. The method of claim 7, wherein the solution administered contains magnesium gluconate at a dose range of approximately 0.2M to 0.4M.
9. The method of claim 7, wherein the solution is administered enterally.
10. The method of claim 7, wherein the solution is administered parenterally.
11. A method for treating reperfusion injury comprising the step of administering to a patient at risk of a reperfusion injury a therapeutically effective amount of magnesium gluconate.
12. The method of claim 11, wherein the magnesium gluconate is administered in an aqueous solution.
13. The method of claim 12, wherein the solution administered contains magnesium gluconate at a dose range of approximately 0.2M to 0.4M.
14. The method of claim 12, wherein the solution is administered enterally.
15. The method of claim 12, wherein the solution is administered parenterally.
16. A method for treating reperfusion injury comprising the step of administering to a patient prior to an expected ischemic event or after onset of an ischemic event a therapeutically effective amount of magnesium gluconate.
17. The method of claim 16, wherein the magnesium gluconate is administered in an aqueous solution.
18. The method of claim 17, wherein the solution administered contains magnesium gluconate at a dose range of approximately 0.2M to 0.4M.
19. A method for preventing atherosclerosis or restenosis in cardiac and endothelial tissue comprising administering a therapeutically effective amount of magnesium gluconate to inhibit oxygen free radical production.
20. The method of claim 19, in which the magnesium gluconate is administered to a patient prior to or after coronary artery bypass or angioplasty.
21. A method for preventing reperfusion injury comprising the step of administering a therapeutically effective amount of magnesium gluconate to a patient at risk of a reperfusion injury.
22. The method of claim 21, wherein the magnesium gluconate is administered to a patient prior to an expected ischemic event or after onset of an ischemic event.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58856496A | 1996-01-18 | 1996-01-18 | |
| US08/588,564 | 1996-01-18 | ||
| PCT/US1997/000821 WO1997025959A2 (en) | 1996-01-18 | 1997-01-17 | Compositions and methods for the prevention and treatment of atherosclerosis and reperfusion injury with magnesium salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2243313A1 true CA2243313A1 (en) | 1997-07-24 |
Family
ID=29422852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2243313 Abandoned CA2243313A1 (en) | 1996-01-18 | 1997-01-17 | Compositions and methods for the prevention and treatment of atherosclerosis and reperfusion injury with magnesium salts |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2243313A1 (en) |
-
1997
- 1997-01-17 CA CA 2243313 patent/CA2243313A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Babbitt et al. | Intracoronary adenosine administered after reperfusion limits vascular injury after prolonged ischemia in the canine model. | |
| Smith et al. | Gastric mucosal injury in the rat: Role of iron and xanthine oxidase | |
| TW577736B (en) | A pharmaceutical composition for cerebral function improvement | |
| Dworkin et al. | Renal vascular effects of antihypertensive therapy in uninephrectomized SHR | |
| KR0128287B1 (en) | Pharmaceutical composition for the inhibition of angiogenesis | |
| US5095027A (en) | Method for treating reperfusion injury employing L-2-oxothiazolidine-4-carboxylic acid | |
| Heiss et al. | Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA | |
| WO2002003996A1 (en) | Use of dammarane-type tritepenoid saporins | |
| Babbitt et al. | Intracoronary adenosine administration during reperfusion following 3 hours of ischemia: effects on infarct size, ventricular function, and regional myocardial blood flow | |
| US5843996A (en) | Intravenous magnesium gluconate for treatment of conditions caused by excessive oxidative stress due to free radical distribution | |
| Bose et al. | SOHO state of the art updates and next questions: identifying and treating “progression” in myelofibrosis | |
| WO1997025959A2 (en) | Compositions and methods for the prevention and treatment of atherosclerosis and reperfusion injury with magnesium salts | |
| Tripodi et al. | Successful treatment with ampicillin and fluoroquinolones of human endocarditis due to high-level gentamicin-resistant enterococci | |
| JPH06172175A (en) | Method for prophylaxis and therapy of atherosclerosis | |
| EP0305181A2 (en) | Ethyl-(+)-apovincaminate for treating demyelinization clinical patterns of autoimmune origin | |
| Katz | The expanding role of oxygen free radicals in clinical medicine | |
| CA2243313A1 (en) | Compositions and methods for the prevention and treatment of atherosclerosis and reperfusion injury with magnesium salts | |
| JPH05507908A (en) | Method of treatment with HSP70 | |
| US4049795A (en) | Treatment of hemorrhagic shock | |
| EP1190714A2 (en) | Method for the treatment of thromboembolic disorders in patients with aspirin resistance | |
| JP2000510114A (en) | Antioxidant compounds | |
| US20050182136A1 (en) | N-acetylcysteine compositions and methods for the treatment and prevention of endothelial dysfunction | |
| PT1381364E (en) | Use of mangafodipir for treating hepatocellular insufficiency | |
| Zurovsky et al. | Glycerol-induced augmentation of sensitivity to endotoxin in rats | |
| Onoyama et al. | Use of recombinant tissue‐type plasminogen activator to treat massive pulmonary embolism after cesarean section: a case report |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |